ArticleSubstance use & misuse2026
Comparing Buprenorphine Treatment Outcomes Among Kentucky Medicaid Patients by Prescriber Specialty and Type.
Article in Substance use & misuse, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundBuprenorphine is vital to improving health outcomes for patients with opioid use disorder (OUD). Little is known about variation in buprenorphine retention and related outcomes across different outpatient prescribers and settings.
methodsOur 2020-2021 sample includes 10,709 Kentucky Medicaid-enrolled patients with OUD who received most of their buprenorphine prescriptions from primary care physicians, specialty care physicians, or advanced practice providers (APP). Adjusted multivariable linear and logistic regression, respectively, estimated the percentage of days with buprenorphine coverage and the proportion of patients who experienced non-fatal overdose after the first prescription.
resultsCompared to specialty physicians and APPs, those with primary care prescribers had a higher percentage of days with buprenorphine (primary: 69.6, 95% confidence interval (CI): [66.7, 72.4]; specialty: 60.1, 95% CI: [54.7, 65.4]; APP: 64.3, 95% CI: [62.1, 66.5];
conclusionsKentucky Medicaid-enrolled patients with primary care physicians had the highest treatment retention, while patients with APPs were less likely to experience a non-fatal overdose. Our findings suggest that although multiple provider types can effectively prescribe buprenorphine, the potentially meaningful differences observed in retention and non-fatal overdose warrant further longitudinal investigation to assess whether these differences by provider type and setting persist over time.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.